Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Recovering from budget neglect requires a clear plan: rebuild essential budgets, tackle debt strategically, and track progress weekly.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Bitcoin steadies as US-Iran tensions ripple through oil and inflation bets. Analysts say these forces could push BTC ...
Escrow audits are back in focus as regulators tighten oversight. Title agencies are adopting a formal escrow audit re...
Ethereum and Solana are trading well off their peaks as upgrades loom. The market is debating which will hit a new AT...
Florida’s housing market finds footing in late May 2026 as pending sales rise and inventory stabilizes. Sellers face ...
Mega-cap IPOs from SpaceX and Anthropic are approaching, potentially reshaping index fund rules and 401(k) allocation...
Tech-led gains push major indices higher on June 9, 2026, with the S&P 500 and Nasdaq leading the rally as investors ...
A new Harvard study shows the income needed to afford median-priced homes has nearly doubled since 2020, highlighting...
A high-profile Ethereum MEV exploit tied to the Jaredfromsubway bot has seen the attacker move millions via Tornado C...
Prime Day results defy pessimism as consumers keep shopping online and Amazon’s cloud growth supports the stock. The ...
Rising U.S. rents spur interest in a dividend portfolio that pays rent-like income. Analysts compare yields from REIT...
As gig work grows, Solo 401K options offer a powerful retirement path for Uber and DoorDash drivers. Yet many workers...